Stryker Corporation (SYK) Free Cash Flow CAGR:27.79%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Stryker Corporation's Free Cash Flow CAGR averages 26.33% over 3 years and 11.01% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how Stryker Corporation's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
SYK Free Cash Flow CAGR Chart
Stryker Corporation (SYK)
SYK Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
SYK Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $3.49B | $4.28B | +$796.00M | +22.83% | +22.83% |
| 2024 | $3.14B | $3.49B | +$351.00M | +11.19% | +11.19% |
| 2023 | $2.04B | $3.14B | +$1.10B | +54.03% | +54.03% |
| 2022 | $2.74B | $2.04B | $-702.00M | -25.64% | -25.64% |
| 2021 | $2.79B | $2.74B | $-52.00M | -1.86% | -1.86% |
| 2020 | $1.54B | $2.79B | +$1.25B | +80.93% | +80.93% |
| 2019 | $2.04B | $1.54B | $-496.00M | -24.34% | -24.34% |
| 2018 | $961.00M | $2.04B | +$1.08B | +112.07% | +112.07% |
| 2017 | $1.43B | $961.00M | $-464.00M | -32.56% | -32.56% |
| 2016 | $629.00M | $1.43B | +$796.00M | +126.55% | +126.55% |
| 2015 | $1.55B | $629.00M | $-920.00M | -59.39% | -59.39% |
| 2014 | $1.69B | $1.55B | $-142.00M | -8.40% | -8.40% |
| 2013 | $1.45B | $1.69B | +$244.00M | +16.86% | +16.86% |
| 2012 | $1.21B | $1.45B | +$239.00M | +19.78% | +19.78% |
| 2011 | $1.37B | $1.21B | $-157.30M | -11.52% | -11.52% |
| 2010 | $1.33B | $1.37B | +$35.90M | +2.70% | +2.70% |
| 2009 | $1.02B | $1.33B | +$308.70M | +30.24% | +30.24% |
| 2008 | $840.60M | $1.02B | +$180.10M | +21.43% | +21.43% |
| 2007 | $649.80M | $840.60M | +$190.80M | +29.36% | +29.36% |
| 2006 | $592.10M | $649.80M | +$57.70M | +9.74% | +9.74% |
| 2005 | $405.50M | $592.10M | +$186.60M | +46.02% | +46.02% |
| 2004 | $504.00M | $405.50M | $-98.50M | -19.54% | -19.54% |
| 2003 | $364.90M | $504.00M | +$139.10M | +38.12% | +38.12% |
| 2002 | $306.40M | $364.90M | +$58.50M | +19.09% | +19.09% |
| 2001 | $251.10M | $306.40M | +$55.30M | +22.02% | +22.02% |
| 2000 | $207.80M | $251.10M | +$43.30M | +20.84% | +20.84% |
| 1999 | $-1.59B | $207.80M | +$1.80B | N/A | N/A |
| 1998 | $56.70M | $-1.59B | $-1.65B | -2906.70% | N/A |
| 1997 | $177.60M | $56.70M | $-120.90M | -68.07% | -68.07% |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $415.00M | -77.9% | +226.8% |
| Q4 2025 | $1.88B | +38.6% | +12.6% |
| Q3 2025 | $1.35B | +45.8% | +3.8% |
| Q2 2025 | $928.00M | +630.7% | +92.9% |
| Q1 2025 | $127.00M | -92.4% | +243.2% |
| Q4 2024 | $1.67B | +27.7% | +20.4% |
| Q3 2024 | $1.30B | +171.1% | +44.6% |
| Q2 2024 | $481.00M | +1200.0% | -10.3% |
| Q1 2024 | $37.00M | -97.3% | -88.3% |
| Q4 2023 | $1.38B | +53.3% | +69.7% |
| Q3 2023 | $902.00M | +68.3% | +20.1% |
| Q2 2023 | $536.00M | +70.2% | +38.9% |
| Q1 2023 | $315.00M | -61.3% | +275.0% |
| Q4 2022 | $815.00M | +8.5% | +2.6% |
| Q3 2022 | $751.00M | +94.6% | -6.5% |
| Q2 2022 | $386.00M | +359.5% | -50.0% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo